For whom is it indicated: Peopleas con sueo lighto
GLP-1 Medications: The Metabolic Component GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are the metabolic backbone of this stack
Its activity intersects two major metabolic pathways simultaneously: the NAD+ biosynthesis pathway (by consuming nicotinamide, an NAD+ precursor, NNMT competes with the NAD+ salvage pathway) and the methyl-donor pathway (by consuming SAM, NNMT reduces the availability of methyl groups for epigenetic and metabolic methylation reactions)
Limited Human Safety Data : BPC-157 has mostly preclinical evidence, and recent reviews state that well-designed human trials are still needed to assess safety, effectiveness, and clinical value
Read that list as a set of research directions, not promises